Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2

Lloyd Paul Aiello, Louis Vignati, Matthew J Sheetz, Xin Zhi, Aniz Girach, Matthew D Davis, Anne M Wolka, Nazila Shahri, Roy C Milton, PKC-DRS and PKC-DRS2 Study Groups

91 Citationer (Scopus)

Abstract

To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very severe nonproliferative diabetic retinopathy from the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 ruboxistaurin (RBX) protein kinase C β inhibitor trials.
OriginalsprogEngelsk
TidsskriftRetina
Vol/bind31
Udgave nummer10
Sider (fra-til)2084-94
Antal sider11
ISSN0275-004X
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2'. Sammen danner de et unikt fingeraftryk.

Citationsformater